Kane Black
Angel Investor
Singapore, Singapore
Kane Black is a angel investor in Singapore. A seasoned technology entrepreneur, with an extensive and diverse international career in senior and executive leadership across the technology, biotechnology, medical device and healthcare investment sectors globally.Mr. Black began his career with Tokyo Stock Exchange (Jasdaq) listed semiconductor trading company Adtec Corporation K.K (nowknown as AKIBA Holdings (6840:Tokyo) becoming Director and Head of Operations for Europe, based in London U.K. In 2005 he was instrumental in the takeover of Adtec Corporation by Japanese technology company Shinden Hightex Corporation (3131:Tokyo) and remained a Director with the company, based in London.In 2012 he co – founded Nova Satra Health to leverage the latest developments in medical technologies with a view to developing, collaborating and commercialising these cutting-edge therapies across the med tech spectrum. This led, in 2014, to the establishment of Singapore based molecular diagnostic developer Nova Satra Dx Pte Ltd.In August 2019 Nova Satra Dx merged with another women’s health focused molecular diagnostics developer, INEX Innovations Exchange in a US$72 Million deal - creating INEX Innovate.In 2020 Mr. Black was invited to sit as Council Member of the National University of Singapore's, NUS Medicine International Council and in 2022 was selected as EY Singapore Entrepreneur of the Year - Biotechnology
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Stages Kane Black invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Nova Satra Dx is a molecular diagnostics company headquartered in Singapore. The company is committed to empowering patients and physicians through the research, development and commercialisation of novel blood based diagnostic tests. These tests provide rapid and accurate detection of cancer using Asian-specific epigenetic biomarkers. Based onits clinically validated NovoTect™ technology developed by the University of Oxford, Nova Satra’s diagnostic tests can detect and identify changes in gene expression which are linked to cancer. The company is developing a pipeline of tests for breast, colon, prostate, stomach and lung cancers. For more information, please visit www.novasatra.com | $500K / Angel / Oct 01, 2014 |
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
FAQ
How do I contact Kane Black?
Public channels for Kane Black include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kane Black last invest?
The most recent investment recorded for Kane Black closed in Oct 2014. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
